Vera Therapeutics announced that its ORIGIN Phase 3 trial of atacicept for IgA nephropathy met its primary endpoint, showing statistically significant and clinically meaningful reductions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback